The Greece cancer test: www.rgcc-genlab.com
Research Genetic Caner Centre (R.G.C.C.) located in Greece has developed a revolutionary test that is changing our perception of cancer as well as the ways we can defeat it.
R.G.C.C. is a genetic research laboratory that has developed a patented membrane that is able to capture malignant cells from your own blood. It is capable of capturing one malignant cell out of trillions of normal blood cells. It is so specific it can actually give a count of malignant cells captured per milliliter of blood that is sent to Greece.
Once the scientist have captured the malignant cells on the membrane they are able to grow or culture the cells outside of your body on cell culture dishes. Next, over six days they test the cultures with all the modern chemotherapy agents, over 70 natural agents, as well as the genetic expression of the cancer itself. At the end of the six days of testing all of these agents, the scientist give a percentage of kill rate or percentage of decrease of the malignant cells in the cell culture dishes. The gene expression part of the test allows us to really look at how the malignant cells want to grow, multiply, develop new blood vessels, grow in other places (metastasis), what feeds it and what inhibits it. This information allows your oncologist or practitioners get a specific look and insight on which therapy may work best for you. It allows oncologist to be specific with their chemotherapy treatments and also allows you and other practitioners to know what may be the best natural approach to cancer therapy as well.
In our office we have had incredible results using immunotherapy agents in IV and oral therapy by following the specific results of the Greece test. This test allows your doctor to use the precise agents to determine the best outcome for your long-term health.
The test is being run by some of the largest cancer hospitals in the world including M.D. Anderson. Most patients know they have cancer when they come to see us, so we expect the results to show a positive culture. However, the test is also for patients who have overcome cancer and want to make sure it is truly gone on a chemical level, even though they may be clear to all scans run by their doctor. It is also for those people who have a family history and want to be tested preventively, even before a tumor can be detected or develop or seen on any scan.
A new outlook on cancer is that cancer is a systemic problem, even from the beginning, even if cancer is removed early. We know now that cancer as small as 2 mm has spread blood vessels into our normal blood stream and shared information with your other immune cells, genes and peptides. This means that cancer may develop metastasis at some time in the future, sooner or later and just cutting it out radiating the area may not prevent it from spreading. Also, even though a patient may be years from their original diagnosis and they may be clear to all scans doesn’t mean that malignant cells aren’t floating in their bloodstream and given the proper environment may land somewhere and grow again. The Greece test gives us the ability to help people on initial diagnosis and ensure a stress-free long-term health.
Dendritic Cell Vaccine (Immune Support Therapy)
Research Genetic Cancer Centre (R.G.C.C.) is capable of collecting a patient’s cancer cell from a simple blood draw. The dendritic cell therapy that is used in this treatment is created from the patient’s own circulating tumor cells presenting antigen. This is not a gene therapy and no toxic drugs are used. The presiding research paper is presented below this article. The RGCC dendritic preparation is similar to most others yet different in the fact that it is made from the patients circulating tumor cells unique peptides. It is an active cellular immunotherapy which involves programming antigen-presenting autologous dendritic cells from the patient following extraction from the patient’s blood. The main goal of the therapeutic vaccine is to elicit cellular immunity. These cells can prime naive T cells as well as induce transition from chronically un-activated T cells to programmed activated T cells that are capable of producing cytotoxic T lymphocytes that recognize and eliminate cancer cells in an antigen-specific way and also provide a long acting memory that will act to prevent relapse. The most critical step in vaccination is the effective presentation of cancer antigens to T cells and since dendritic cells are the most efficient antigen presenting cells, they are the promising option for improvement of therapeutic vaccines. This method by RGCC is both testable and trackable. The cells are incubated for 12 days then returned to the patient to generate an immune response.
What are Dendritic Cells?
Dendritic cells are antigen-presenting cells to special immune cells. They are special key regulators of the Immune system capable of activating the T-Cells and stimulating the growth and differentiation of B-Cells. These cells will attach to the cancer cells as well as provide long lasting immunity. The roles of Dendritic Cells are to recognize process and present the foreign antigens to the T-cells therefore creating a constant therapy for the patient.
Dendritic Cells to sustain minimal residual disease article:
Click here NIH Dendritic cell Therapy: https://www.ncbi.nlm.nih.gov/pubmed/10073291
Individualized dendritic vaccines are created by isolating the cancer cells to identify the most frequently expressed protein (epitope) on the surface of the cancer cells. This cancer protein is then imprinted on to the dendritic cells. The dendritic cell population is then augmented to multi-millions and this is introduced to the patient.
Goal of Vaccine
The goal of the vaccine is to educate dendritic cells to teach T cells and B cells how to recognize the cancer cell. And eventually CD28 cells form memory to teach new dendritic cells their same execution. If the vaccine “takes” it will give long-term immunity to the cancer cells. Booster Vaccines can be made in the future for the patient if the dendritic cells or the CD28 cells lose any strength or memory.
Protocol for Dendritic Cell Therapy
- Before we start on the Dendritic Cell Therapy, we proceed with a blood test called the Immune-Frame. This blood test checks to see if the T-Cells (CD86) and B Cells (CD80) are within acceptable range and patient is a candidate. This takes up to one month to receive results. CD80 is the protein molecule found on dendritic cells that activates B-Cells. CD86 is the protein molecule found on dendritic cells that provide the initial co-stimulatory signal that activates T-Cells. CD80 and CD86 work together to form the best T-Cells to fight any foreign invasion. CD28 memory cells are measured as well to develop a continued programming of dendritic cells.
- Appointment for consult with physician will be scheduled to go over results of Immune-Frame and immune system modulation may be needed before the administration of the dendritic cell therapy.
- Next, blood is drawn and sent to RGCC labs to have the dendritic cell created.
- As we wait for the dendritic cells to arrive on the precisely scheduled date that is pre-arranged, please continue any and all current therapies until this date.
- All blood draws to be done ONLY on MONDAY to be sent off on same day.
- Please be prepared to be in our office day 24-27 from this pre-arranged date due to shipping differences. These are live dendritic cells and are time sensitive.
- It takes 4-5 hours for the vaccine infusion to be done. Certain immune reactions are expected and these will be discussed.
- The 2nd Immune Frame (IF) is then drawn at 3-6 weeks to look for CD80 and CD86 increase to 25%. If CD80 and CD86 have less than 25%, then a booster vaccine may be given next.
- If 2nd dose of the vaccine is required, it has to be ordered immediately and protocol remains the same for the duration.
- If the 3-6 week Immune-Frame blood draw results has over 25% increase in CD80 and CD86, then we will wait 8-12 weeks for another Immune Frame blood draw to confirm CD28 which are memory cells to be checked as these cells are “Librarians” to provide permanent education to continue for long-term immunity.
- There will be a third Immune Frame (IF) test performed, either after the booster vaccine or as planned to test the dendritic cells as they grow and develop through your immune system.
- At this point, as we measure the dendritic cells increasing in strength and we see the develop of CD28 memory cells, a fourth Immune Frame may be needed 8-12 weeks from the third test to measure further development of the CD80/86 and CD28 memory cells
- From this point, every six months we draw the Immune-Frame blood test to measure and verify that the dendritic cells are maintaining over 25% stability. In the future, if the cells lose any strength then a booster vaccine is given once again. This verifies that we maintain the most minimal residual disease for as long as possible.
Types of cancers that do not work with IST (Immune Support Therapy) – Dendritic vaccine
Anaplastic cancers with poor cellular differentiation losing morphological characteristics of mature cells and their orientation with respect to each other and to endothelial cells will not work.
CNS cancers have to be biopsied in order to create IST (Immune Support Therapy) and it becomes less of a chance it will work as well as it does with other cancers.
Frequently asked questions:
What are dendritic cells, and why are they useful?
Dendritic cells are in every person’s bloodstream and are a blood cell. They normally function as an immune cell but are present in very small numbers, somewhat like an elite force. Their usual function is to identify a foreign substance, including cancer cells, and process the bits of such foreign substances and then jumpstart the immune response by bringing the foreign substance to the attention of the rest of the immune system (mostly T lymphocyte cells). The activated immune system is then able to circulate throughout the body and destroy the cancer cells.
What kind of cancers can be treated with Dendritic Cell therapy?
Theoretically all cancers can be treated, but experience tells us that certain cancers such as melanoma and kidney cancer should respond best. To date, therapeutic benefit has been documented in B cell lymphoma, myeloma, melanoma, prostate cancer, colon cancer, ovarian cancer, breast cancer, and renal cell cancer amongst others. If interested, patients should seek professional advice on specific cancer and dendritic cell therapy and carefully weigh their treatment options. There are currently active trials using dendritic therapy in melanoma and kidney cancer. Dendritic cell therapy is currently used in melanoma and prostate cancer in the USA but only when the cancer enters stage 4.
At what cancer stage should a patient consider Dendritic Cell therapy?
A patient can consider dendritic cell therapy when all other options have been exhausted, or if the disease is stable and the patient is not on any chemo or radiation therapies concurrently, or if the patient is free of disease but at risk for recurrence and is seeking to potentially reduce the likelihood of cancer reoccurrence. In general, patients should generally seek professional advice on specific cancers and carefully weigh treatment options before proceeding with specific therapy.
Can leukemia/lymphoma be treated with Dendritic Cell therapy?
Yes. Any Cancer that a Circulating tumor cell can be found in the blood will be tested to see if a Dendritic cell treatment can be performed.
Can childhood tumors be treated with Dendritic Cell therapy?
Yes, and experience is accumulating in this area. Patient’s guardians should seek professional advice on specific cancers regarding dendritic cell therapy and carefully weigh their treatment options (See review)
Is Dendritic Cell Therapy safe?
Multiple studies including human trials and as well as clinical experience have established the treatment as generally safe. Usual short term side effects: fatigue, headache, chills, low grade fever (99-100F). Occasionally a mild rash may appear lasting 3 to 14 days. There have never been any reported anaphylactic reactions (severe life threatening) from this procedure.
Are there any contraindications to Dendritic Cell Therapy?
Recent radiation and chemotherapy which tends to depress the immune system may be contraindications to dendritic cell therapy. Immunologic testing can better establish the condition of the immune system to help physicians determine if a patient is a good candidate for dendritic cell therapy. This test is called the Immune Frame from RGCC Labs. Recent blood transfusions, active autoimmune disease as well as pregnancy are also possible contraindications. Contraindications should be carefully discussed and reviewed with the consulting physician before proceeding.
Are there any clinical trials I can take part in?
There are a number of domestic trials in the US as well as start-up elsewhere in the world that you may qualify for, particularly for melanoma, prostate, renal cell cancer, and other solid tumors and leukemia as well. You should refer to our clinical trials section for more information to see if you are eligible.
What if a patient is not qualified for any active trials?
One can consider private treatment in Europe or elsewhere out of a trial setting if one is not eligible for clinical trials. Also, select private clinics in the USA may offer dendritic cell therapy. If seriously interested or you need help in sorting out the pros and cons of various trials vs. private treatments as well as the details of the actual dendritic dell therapy protocols involved, one should consider a consultation with a reputable and knowledgeable physician to discuss choice of trials, prognosis and possible outcome as well as logistical details relating to dendritic cell therapy.
Mack H Sloan, ND, DPH